During the past decade, DaVita Clinical Research conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 18 clinical trials were completed, i.e. on average, 32.7% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 12 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "DaVita Clinical Research" #1 sponsor was "Novartis Pharmaceuticals" with 6 trials, followed by "Bristol-Myers Squibb" with 5 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Celgene" with 4 trials sponsored and "Boehringer Ingelheim" with 4 trials sponsored. Other sponsors include 61 different institutions and companies that sponsored additional 64 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "DaVita Clinical Research" #1 collaborator was "Davita Clinical Research" with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Basilea Pharmaceutica International Ltd" with 1 trials as a collaborator and "Fresenius Medical Care North America" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "DaVita Clinical Research" are "Hepatic Impairment" (8 trials), "Renal Impairment" (6 trials), "Chronic Kidney Disease" (4 trials), "End Stage Renal Disease" (4 trials) and "Diabetic Nephropathies" (3 trials). Many other conditions were trialed in "DaVita Clinical Research" in a lesser frequency.

Most popular intervention types in "DaVita Clinical Research" are "Drug" (74 trials), "Other" (7 trials), "Device" (4 trials), "Biological" (3 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "BI 685509" (2 trials), "Bardoxolone methyl oral capsule" (2 trials), "LY3113593" (2 trials) and "Placebo oral capsule" (2 trials). Other intervention names were less common.

The vast majority of trials in "DaVita Clinical Research" are 87 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "DaVita Clinical Research". 1 are not yet recruiting, 8 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 69 completed trials in DaVita Clinical Research, 1 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in DaVita Clinical Research, 50 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 9 trials that are defined as “Not Applicable".